In vivo Anticancer Potential of Hydroxamic Acid Derivatives

被引:6
作者
Li, Huanting [1 ]
Gong, Yufeng [2 ]
Zhong, Qinyan [3 ]
机构
[1] Baotou Med Coll, Dept Pharm, Baotou 014040, Inner Mongolia, Peoples R China
[2] Mudanjiang Med Univ, Affiliated Hosp 2, Mudanjiang 157000, Peoples R China
[3] Zhuji Peoples Hosp, Zhuji 311800, Peoples R China
关键词
Hydroxamic acid; Hybrid molecules; In vivo; Cancer; Mechanisms of action; Anticancer drug discovery; Histone deacetylases; HISTONE DEACETYLASE INHIBITORS; BREAST-CANCER; ANTITUMOR-ACTIVITY; HDAC INHIBITOR; TUMOR-GROWTH; VITRO; DESIGN; DISCOVERY;
D O I
10.2174/1568026621666210813105240
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Notwithstanding the noteworthy advances in its treatment, cancer remains one of the most serious threatens to humans across the world. Hydroxamic acid derivatives, the potential inhibitors of Histone Deacetylases (HDACs), could inhibit cancer cell proliferation, induce cell differentiation, apoptosis and autophagy, and suppress angiogenesis, invasion as well as metastasis through diverse signaling pathways. Thus, hydroxamic acid derivatives exhibit promising activity against cancers and are useful scaffolds in modern anticancer drug discovery. The purpose of the present review article is to summarize the recent developments (Jan, 2011-Jan, 2021) in hydroxamic acid derivatives with insights into their in vivo anticancer potential and mechanisms of action.
引用
收藏
页码:1737 / 1755
页数:19
相关论文
共 85 条
  • [1] Methods for Hydroxamic Acid Synthesis
    Alam, Mohammad A.
    [J]. CURRENT ORGANIC CHEMISTRY, 2019, 23 (09) : 978 - 993
  • [2] Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery
    Amin, S. K. Abdul
    Adhikari, Nilanjan
    Jha, Tarun
    [J]. FUTURE MEDICINAL CHEMISTRY, 2017, 9 (18) : 2211 - 2237
  • [3] Sulfonamide derivatives as multi-target agents for complex diseases
    Apaydin, Sinem
    Torok, Marianna
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (16) : 2042 - 2050
  • [4] Recent advances in class IIa histone deacetylases research
    Asfaha, Yodita
    Schrenk, Christian
    Avelar, Leandro A. Alves
    Hamacher, Alexandra
    Pflieger, Marc
    Kassack, Matthias U.
    Kurz, Thomas
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (22)
  • [5] Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids
    Auti, Prashant S.
    George, Ginson
    Paul, Atish T.
    [J]. RSC ADVANCES, 2020, 10 (68) : 41353 - 41392
  • [6] Research Advances in the Use of Historic Deacetylase Inhibitors Epigenetic Targeting cif Cancer
    Bai, Yu
    Ahnlad, Daid
    Wang, Ting
    Cui, Guihua
    Li, Wenliang
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2019, 19 (12) : 995 - 1004
  • [7] Therapeutic progression of quinazolines as targeted chemotherapeutic agents
    Bansal, Ranju
    Malhotra, Anjleena
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 211
  • [8] The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
    Bassett, Shalome A.
    Barnett, Matthew P. G.
    [J]. NUTRIENTS, 2014, 6 (10): : 4273 - 4301
  • [9] Inside HDAC with HDAC inhibitors
    Bertrand, Philippe
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (06) : 2095 - 2116
  • [10] Structural Activity Relationship and Importance of Benzothiazole Derivatives in Medicinal Chemistry: A Comprehensive Review
    Bhat, Mahesh
    Belagali, Shiddappa Lagamappa
    [J]. MINI-REVIEWS IN ORGANIC CHEMISTRY, 2020, 17 (03) : 323 - 350